Cencora, Inc. (NYSE:COR) Shares Sold by M3 Advisory Group LLC

M3 Advisory Group LLC lowered its position in shares of Cencora, Inc. (NYSE:COR) by 2.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,783 shares of the company’s stock after selling 45 shares during the period. M3 Advisory Group LLC’s holdings in Cencora were worth $401,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Insight Wealth Strategies LLC raised its position in Cencora by 124.6% in the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after purchasing an additional 11,232 shares during the period. Cerity Partners LLC grew its holdings in shares of Cencora by 10.1% during the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after purchasing an additional 3,610 shares during the period. Thurston Springer Miller Herd & Titak Inc. increased its position in shares of Cencora by 71.1% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company’s stock worth $1,583,000 after purchasing an additional 2,928 shares during the last quarter. Portfolio Design Labs LLC purchased a new stake in Cencora in the 3rd quarter valued at about $1,404,000. Finally, Mackenzie Financial Corp boosted its stake in Cencora by 9.9% during the second quarter. Mackenzie Financial Corp now owns 81,001 shares of the company’s stock worth $18,250,000 after buying an additional 7,266 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares in the company, valued at $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock worth $17,790,912 in the last 90 days. Corporate insiders own 15.80% of the company’s stock.

Cencora Price Performance

COR stock opened at $248.45 on Friday. The business’s 50-day moving average is $237.51 and its two-hundred day moving average is $234.75. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The firm has a market capitalization of $48.02 billion, a P/E ratio of 33.08, a P/E/G ratio of 1.54 and a beta of 0.49. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is currently 29.29%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird boosted their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. UBS Group boosted their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Barclays raised their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective on the stock. Finally, Wells Fargo & Company decreased their target price on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research note on Friday, December 13th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $277.00.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.